Intra-Cellular Therapies
ITCI
#1827
Rank
A$14.15 B
Marketcap
$133.47
Share price
-0.82%
Change (1 day)
36.03%
Change (1 year)

Revenue for Intra-Cellular Therapies (ITCI)

Revenue in 2024 (TTM): A$0.90 Billion

According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM ) is A$0.98 Billion. In 2023 the company made a revenue of A$0.67 Billion an increase over the revenue in the year 2022 that were of A$0.36 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Intra-Cellular Therapies from 2014 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) A$0.90 B34.06%
2023 A$0.67 B85.3%
2022 A$0.36 B224.83%
2021 A$0.11 B284.64%
2020 A$29.3 M33746.09%
2019 A$0.08 M
2018 N/A
2017 N/A
2016 N/A-100%
2015 A$0.04 M-93.71%
2014 A$0.66 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
A$16.4 M-98.33%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.13 B-86.10%๐Ÿ‡บ๐Ÿ‡ธ USA